Geron discontinues late-stage trial of blood cancer drug
GERN•Geron will discontinue a late-stage trial of Rytelo for myelofibrosis after an independent data monitoring committee said it was unlikely to achieve its main goal of overall survival. Geron shares were halted in premarket trading.
1. Trial discontinued
Geron said it would discontinue the trial evaluating Rytelo in patients with myelofibrosis after an independent data monitoring committee recommended ending it because it was unlikely to achieve its main goal of overall survival. Rytelo received U.S. approval in 2024 to treat transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromes.
